Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept pRNFL Assessment in Unilateral BRVO
NCT06146309Completed
- Sponsor
- Al-Azhar University
- Start
- Dec 2020
- Primary completion
- Jul 2022
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label trial of aflibercept in branch retinal vein occlusion (BRVO) (2 arms), sponsored by Al-Azhar University. Primary endpoint: peri-papillary retinal nerve fiber layer thickness. Started Dec 2020; status: completed.
02
Drugs
aflibercept
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT06146309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06146309.